Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.

Erik Allen Imel Kathryn Starzyk R Gliklich Richard J Weiss Yamei Wang Setareh A Williams

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2020)

Patients initiating ABL and TPTD differed in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use compared with those initiating DMAB.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
squamous cell carcinoma
emergency department
tyrosine kinase
body composition
health insurance
postmenopausal women
rectal cancer